IGUK21105 // MK-6482-022 // SAHASRABUDHE
Basic Study Information
Purpose:Location: University of Rochester Medical Center ( Site 3528)
The purpose of this study is to assess the efficacy and safety of oral belzutifan
(MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab,
in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
The primary study hypothesis is that belzutifan plus pembrolizumab is superior to
placebo plus pembrolizumab with respect to disease-free survival (DFS).
Lead Researcher (Principal Investigator)
Deepak Sahasrabudhe, MD
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search